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Abstract
AIM
To study hepatic vasoconstriction and glucose release induced 
by angiotensin (Ang)Ⅱ or Epi in rats with pharmacological 
hypertension and spontaneously hypertensive rat (SHR).
METHODS
Isolated liver perfusion was performed following portal 
vein and vena cava cannulation; AngⅡ or epinephrine 
(Epi) was injected in bolus and portal pressure monitored; 
glucose release was measured in perfusate aliquots. 
RESULTS
The portal hypertensive response (PHR) and the glucose 
release induced by AngⅡ of L-NAME were similar to 
normal rats (WIS). On the other hand, the PHR induced 
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by Epi in L-NAME was higher whereas the glucose release 
was lower compared to WIS. Despite the similar glycogen 
content, glucose release induced by AngⅡ was lower in 
SHR compared to Wistar-Kyoto rats although both PHR 
and glucose release induced by Epi in were similar. 
CONCLUSION
AngⅡ and Epi responses are altered in different ways 
in these hypertension models. Our results suggest that 
inhibition of NO production seems to be involved in the 
hepatic effects induced by Epi but not by AngⅡ; the 
diminished glucose release induced by AngⅡ in SHR is 
not related to glycogen content.
Key words: Epinephrine; Liver perfusion; Spontaneously 
hypertensive rat; Glucose; Angiotensin Ⅱ; L-NAME 
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Angiotensin (Ang)Ⅱ and epinephrine (Epi) induce 
hemodynamic and metabolic responses in a normal liver. 
These responses are altered in different ways in two 
models of hypertension. We observed that inhibition 
of NO production seems to be involved in the hepatic 
hemodynamic and metabolic effects induced by Epi but 
not by AngⅡ. Furthermore, diminished glucose release 
induced by AngⅡ in spontaneously hypertensive rat is 
not related to glycogen content, but might be due to the 
glycogen phosphorylase activation by AngⅡ.
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INTRODUCTION
The renin-angiotensin-aldosterone system (RAAS) 
regulates blood pressure homeostasis and vascular 
injury and repair responses. This system has been 
associated with diverse physiological functions, but also 
with inflammation, fibrosis, and target-organ damage. 
Local forms of the RAAS have been described in many 
tissues[1-5]. The importance of RAAS in the pathophysiology 
of hypertension has been observed in brain, heart, adrenal 
glands, vasculature, and kidney[6-9].
Several components of RAAS are present in the 
liver, which synthesizes angiotensinogen, a glycoprotein 
that contains the sequence of angiotensin in its amino-
terminal portion. Angiotensin converting enzyme (ACE) 
is a carboxypeptidase present primarily in the perivenous 
region. Besides converting angiotensin (Ang) Ⅰ in AngⅡ, 
it is the major kininase involved in bradykinin degradation 
in the liver[10]. In 1976, Borges et al[11] showed that both 
AngⅠ and AngⅡ infused into the portal vein of a rat 
induced hypertensive effect, and they also demonstrated 
for the first time the conversion of AngⅠ into AngⅡ by 
the rat liver. This hypertensive response induced by Ang
Ⅱ is mediated by AT1 receptor because when losartan 
was co-infused with AngⅡ into the liver portal vein 
it abolished the hypertension response[12]. Captopril 
infusion prevented pressor action of AngⅠ, thus the PHR 
previously attributed to AngⅠ is actually a result of its 
conversion to AngⅡ by hepatic ACE. This conversion is 
rapid, but the portal hypertensive action after AngⅠ in 
bolus injection is significantly delayed compared to AngⅡ 
injection[13]. Metabolic effects induced by AngⅡ, such as 
glucose release and O2 consumption, are only diminished 
in the presence of losartan, which demonstrates that 
these effects are partially dissociated on bivascular liver 
perfusion. Therefore, another receptor besides AT1R might 
also be involved on these AngⅡ hepatic effects[12,14].
ACE inhibition or blockade of angiotensin receptors 
are widely used in clinical medicine in the treatment of 
hypertension. The role of the hepatic RAAS has been 
associated with fibrosis and cirrhosis, and its resulting 
portal hypertension. Up-regulation of hepatic ACE, ACE2 
and AT1R was observed in animal models of fibrosis 
and cirrhosis by bile duct ligation or carbon tetrachloride 
induction[15-17]. AngⅡ, via AT1R, stimulates activation 
of quiescent stellate cells, activates myofibroblasts 
proliferation, and promotes the release of inflammatory 
cytokines, as well as the excessive deposition of ex-
tracellular matrix components[18].
The catecholaminergic sympathetic nervous system 
is another common system with metabolic (glucose and 
lactate release as well as oxygen consumption increase) 
and hemodynamic (vasoconstriction) effects. This system 
plays a key role in blood pressure homeostasis and normal 
metabolism and participates in the pathophysiology of 
many diseases. The liver contains abundant sympathetic 
innervation derived from the hepatic nerve plexus, and 
circulating catecholamines regulate liver tone[19]. The 
presence of the α1- and β-adrenergic receptors on 
hepatocytes was demonstrated in various species like 
catfish, goldfish, and rats[20-22]. In fed state, epinephrine 
(Epi) promotes hepatic glucose production by activation 
of glycogenolysis and, in fasted state, Epi accelerates 
gluconeogenesis[23].
In patients with essential hypertension, plasma 
levels of norepinephrine are significantly elevated and 
the increased sympathetic activity is accompanied by 
diastolic and systolic pressure increases. Neuroadrenergic 
factors may contribute to the maintenance and progression 
of hypertensive state as well as its development[24]. 
A correlation between the RAAS and the sympathetic 
nervous system has also been described. The latter is 
activated by AngⅡand plays a fundamental role in the 
homeostasis of blood pressure control[25]. The multifactorial 
etiology of hypertension has led researchers to postulate, 
over time, various experimental models, each one 
involving one or more mechanisms, contributing to the 
assembly of a human essential hypertension “mosaic”. 
A pharmacological hypertension model is the blockade 
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of nitric oxide synthesis. Biancardi et al[26] showed 
that vasoconstriction in response to L-NAME by the 
sympathetic tone plays an important role in the initiation 
and maintenance of hypertension. The RAAS also 
contributes to high blood pressure in animals chronically 
treated with L-NAME. Chronic treatment with ACE 
inhibitors or AT1 blockers is able to prevent the onset 
of, or reverse, a hypertension and renal injury already 
established, indicating a involvement of RAAS in the 
genesis and maintenance of this hypertension[27]. A 
spontaneously hypertensive rat (SHR) is the widely 
used genetic hypertension model that presents elevated 
sympathetic activity[28]. Although these animals are 
generally considered to be characterized by a low 
activity of circulating RAAS[29], some studies indicate that 
treatment with ACE inhibitors or AT1 receptor blockers 
or both reduces cardiac or renal dysfunction or both of 
these dysfunctions in SHRs[30-32].
Although the liver is not a target organ in phy-
siopathology of hypertension, the presence of AT1 
receptor and ACE may still indicate unknown specific 
roles. Sympathetic hyperactivity was described in most 
models of hypertension[28] but little is known about the 
consequences of this hyperactivity in the liver. Therefore, 
the aim of this work was to evaluate the hepatic response 
to AngⅡ and Epi in hypertension models. Using the 
isolated rat liver perfusion, we studied the vasoconstrictor 
hepatic effect as well as metabolic (glucose release) 
effect of AngⅡ and Epi in two different hypertension 
experimental models: One genetic (SHR) and one 
pharmacological (systemic inhibition of NO synthase).
MATERIALS AND METHODS
Animals 
Adult male Wistar EPM-1 rats (WIS), SHRs (bred by the 
Central Animal House of the Federal University of São 
Paulo - UNIFESP), and Wistar Kyoto (WKY) rats (bred by 
Central House of the University of de São Paulo - USP) 
aged 12-16 wk were used. The animals were housed 
in a conditioned environment and were fed a standard 
laboratory diet (Purina) and water ad libitum. This study 
was conducted according to the International Guiding 
Principles for Biomedical Research Involving Animals[33] 
and was approved by the Ethics in Research Committee 
of UNIFESP (CEP 1455/09).
Experimental groups
After one week of acclimatization, two experimental 
groups were studied: (1) L-NAME, pharmacologic induced 
model of hypertension: Wistar EPM-1 rats received NG-
nitro-L-arginine methylester (0.5 mg/mL) in drinking 
water for 10 d and were compared to healthy, Wistar 
EPM-1 rats; and (2) SHRs were compared to WKY rats.
Indirect systolic blood pressure 
Body weight and tail indirect systolic blood pressure 
(SBP) were recorded weekly. SBP was measured by tail-
cuff plethysmography (NIBP Controller, ADInstruments, 
Australia) in unanesthetized rats that were placed in 
a warm cupboard (45 ℃) for 15 min. SBP values for 
individual rats were obtained from the average of 3-4 
consecutive measurements and were considered valid 
only when these readings did not differ by more than 5 
mmHg. Procedure was performed at least 48 h before 
the perfusion experiments to minimize the influence of 
animal stress on our results. Upon confirmation of animal 
hypertension, perfusion of rat liver in situ was conduct as 
previously described[34].
Glycemia and insulinemia 
Blood samples were collected from the abdominal aorta 
before portal vein cannulation. They were centrifuged at 
3000 rpm to remove red cells, and serum was stored at 
-20 ℃. Glucose was determined by enzymatic method 
(Glucose PAP kit, Labtest Diagnóstica, Sao Paulo, Brazil) 
and the concentration of insulin was determined using 
a direct ELISA kit specific for rat and mouse analysis 
(Millipore, United States).
In situ rat liver perfusion
Monovascular rat liver perfusion was performed as 
previously described[34]. Briefly, the rat was anesthetized 
with urethane, 1.3 g/kg, i.p. (Sigma Chemical Co., United 
States), and hemoglobin-free, nonrecirculating liver 
perfusion was performed. Abdominal and thoracic cavities 
were opened and the portal vein (entry via) and the vena 
cava (exit via) cannulated. The perfusion fluid was Krebs/
Henseleit-bicarbonate buffer, pH 7.4, containing 1 mg/mL 
BSA (Sigma Chemical Co., United States) saturated with 
an oxygen/carbon dioxide mixture (95/5%). Fluid was 
pumped in a constant flow (3-4 mL/min.g liver) through 
a temperature-regulated membrane oxygenator (37 ℃) 
prior to entering the liver via the portal vein. The oxygen 
uptake in the outflowing perfusate was monitored con-
tinuously with a polarigraphic type of probe (Delta OHM 
HD2109.2, Italy) adequately positioned in a chamber 
at the exit of the perfusate. Liver viability was evaluated 
by bile production and oxygen consumption. The portal 
pressure was measured by using a vertically positioned, 
graduated fluid-filled column attached before the 
afferent cannula open to the atmospheric. After 20 min 
of stabilization previously determined (glucose release 
and portal pressure), 2 nmol AngⅡ (Sigma Chemical 
Co., United States) or 40 nmol Epi (Sigma Chemical 
Co., United States) was injected in bolus into the portal 
vein cannula. Aliquots of perfusate were collected (0 and 
every 30 s until 5 min and 6, 8 and 10 min) for glucose 
determination. 
Portal pressure
Portal pressure was recorded during all experiments 
(0, 15, 30 and 45 s and 1-10 min). The portal pressure 
increase was determined over the basal pressure and the 
maximum increase measured. The portal hypertensive 
response (PHR; the area under the curve) was calculated 
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from the graphic: Portal pressure increase vs time after 
agonist injection and expressed as cmH2O.min.
Metabolic effects
Metabolic effects were evaluated on the basis of oxygen 
consumption and glucose release by perfused liver. 
Oxygen consumption was calculated from input-output 
differences expressed as µmol O2 consumed/min.g liver. 
Glucose released was determined in perfusate aliquots 
using an enzymatic method (Glucose PAP kit, Labtest 
Diagnóstica, Sao Paulo, Brazil) and expressed as µmol 
glucose released/min.g liver. This parameter was also 
used to assure the liver viability. The amount of glucose 
released was calculated (area under the curve) from the 
graphic: Glucose increase vs time after agonist injection 
and expressed as µmol/min.g liver.
Glycogen
In order to avoid loss of the liver glycogen content during 
the 30 min of perfusion, a fragment of caudate lobe was 
removed after a rapid exsanguination at the beginning of 
the perfusion procedure. Quantification of the glycogen 
was based on the extraction of the polysaccharide with 
an alkaline solution (30% KOH) and its conversion into 
glucose during the reaction of the exergonic homogenized 
with a solution of sulfuric acid and anthrone[35]. The 
concentration of glycogen (expressed as mg/100 mg 
liver) was determined from a glucose standard curve. 
Furthermore, liver fragments were removed at the end of 
the experiment and processed by the company Histotech 
Teaching Blades (http://www.histotech.com.br/site/). 
The histological analysis of liver glycogen was performed 
using the periodic acid-Schiff (PAS) staining.
Statistical analysis
The results are expressed as mean ± SEM. Comparisons 
were performed by using Student’s t-test and a value of P 
< 0.05 was adopted as the level of significance. Analysis 
was performed using Graph Pad Prism 5.0 program.
RESULTS
Hypertension animal model characterization
Arterial blood pressure of SHR and rats submitted to 
drug hypertension (L-NAME) was evaluated before the 
perfusion experiments. The tail systolic blood pressure 
(mmHg) of L-NAME (169.1 ± 4.8; n = 12) and SHR 
groups (180.2 ± 5.9; n = 10) were higher (t-test, P < 
0.001) when compared to WIS (126.4 ± 2.9; n = 9) 
and Wistar Kyoto (127.0 ± 2.0; n = 15), respectively. 
The glycemia and insulinemia of the rats used in the 
experiments are shown in Table 1; values of glycemia of 
normotensive animals were taken as the reference value. 
The glycemia of both the L-NAME and SHR groups was 
similar when compared to their respective control groups. 
The insulinemia of all groups were within normal range 
(0-118 pmol/L)[36] without difference between groups.
The perfusion experiments were performed in the 
morning when the animals, which have nocturnal habits, 
were in a well-fed state confirmed by hepatic glycogen 
content. No difference in liver glycogen content among 
groups (Table 1) was found. At the end of perfusion 
another fragment of the liver was removed for histo-
logical analysis for glycogen content (PAS staining) and 
compared to the perfused livers of animals left for 24 h of 
fasting. We observed that even after 30 min of perfusion, 
the hepatic glycogen of all groups was noticeably higher 
than in fasted animals (Figure 1).
Liver viability
To ensure liver viability during the period of liver perfusion 
experiment (approximately 30 min), bile production 
and oxygen consumption were monitored. The bile was 
collected before and after injection of Epi or AngⅡ. As 
the bile production before and after agonist injection 
were similar, the arithmetic average was used for 
statistical analysis. The bile production (mL/min.g liver) 
was similar among groups (WIS: 1.2 ± 0.1, n = 16; 
L-NAME: 1.2 ± 0.1, n = 15; WKY: 1.1 ± 0.1, n = 14; 
SHR: 1.1 ± 0.1, n = 13). The oxygen consumption was 
observed throughout the perfusion period ensuring the 
functioning of the organ. The basal oxygen consumption 
(µmol/min.g liver) of SHR (2.5 ± 0.1, n = 14) was lower 
(t-test, P = 0.0151) when compared to WKY (3.2 ± 
0.2, n = 16). This parameter on L-NAME (3.1 ± 0.2, 
n = 15) was similar to WIS (3.2 ± 0.1; n = 17). After 
agonist injection, oxygen consumption was maintained 
but no standard response was observed: It remained 
the same in some experiments and increased in others. 
As the perfusion fluid did not contain glucose, its release 
was observed from the beginning of the experiment. 
Basal glucose release was similar in all groups (Figure 
2A and B); after agonists injection its release continued 
throughout the entire experiment, ensuring hepatic 
viability.
Group Glycemia (mg/dL) n Insulinemia (ng/mL) n Glycogen content (mg/100 mg liver) n
WIS 75.4 ± 4.2 9 2.1 ± 0.4 12 2.9 ± 0.2 10
L-NAME 80.7 ± 7.5 8 2.0 ± 0.4 12 2.3 ± 0.2 10
WKY 76.9 ± 4.0 9 3.8 ± 0.6 12 2.8 ± 0.2 10
SHR 86.2 ± 4.0 8 2.7 ± 0.4 13 2.8 ± 0.2 10
Table 1  Serum parameters and glycogen content
Serum and liver fragment for glycogen content measurement were collected before the liver perfusion experiment. Values are expressed as mean ± SEM. 
Student’s t-test; L-NAME vs WIS and SHR vs WKY. WIS: Similar to normal rats; SHR: Spontaneously hypertensive rat; WKY: Wistar Kyoto.
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Glucose release induced by AngⅡ  or Epi
Following AngⅡ injection, the amount of glucose released 
(Figure 2A and B) from the L-NAME group was similar 
compared to the WIS group, whereas the amount released 
from SHR livers was lower than its WKY control group 
(Table 2).
The glucose release induced by epinephrine is shown 
in Figure 2C and D; the amount released (AUC) from the 
L-NAME group (4.2 ± 0.4) was lower when compared 
to its WIS control group (7.5 ± 0.9), whereas the SHR 
Fed state                                                                        Fasted state
WIS
L-NAME
WKY
SHR
Figure 1  Hepatic glycogen. Periodic acid Schiff’s staining of cross-section of perfused livers from fed or 12 h fasted rats. Fragments taken after 30 min of perfusion. 
Increase 200 ×. WIS: Similar to normal rats; SHR: Spontaneously hypertensive rat; WKY: Wistar Kyoto.
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group was similar to the WKY group (Table 2).
PHR to AngⅡ  or Epi
Basal portal pressure (before agonist injection) was 
similar in all groups. AngⅡ (2 nmol) or Epi (40 nmol) 
was injected in portal vein and both agonists promoted 
portal vasoconstriction. Despite a 20-fold difference in 
agonists doses, the maximum portal pressure increase 
(cmH2O) induced by AngⅡ and Epi was similar in among 
groups (AngⅡ: WIS: 7.9 ± 1.2, n = 7; L-NAME: 7.6 ± 
1.1, n = 7; WKY: 10.5 ± 0.3, n = 7; SHR: 6.5 ± 1.2, n = 
10; Epi: WIS: 6.1 ± 0.7, n = 10; L-NAME: 8.9 ± 0.7, n 
= 8; WKY: 7.9 ± 0.7, n = 8; and SHR: 6.2 ± 0.5, n = 6).
The hepatic portal pressure increase after bolus 
injection of AngⅡ was normalized after about 10 min of 
perfusion (Figure 3A and B). The curve prolife of portal 
pressure of L-NAME and SHR groups was similar to their 
control groups (WIS and WKY, respectively). The PHR 
induced by AngⅡ in both L-NAME and SHR was similar 
when compared to their WIS and WKY control groups, 
respectively (Table 3). The effect of Epi in portal pressure 
was more transient than AngⅡ. Following Epi injection, 
the portal pressure increase was normalized after about 
5 min (Figure 1). The PHR induced by Epi in the L-NAME 
group was higher when compared to the WIS group. 
On the other hand, no difference in PHR of SHRs existed 
compared to the control WKY group (Table 3). 
DISCUSSION
All key components of the RAAS are present in the 
normal liver and are up-regulated in response to chronic 
liver injury, with growing evidence that the intrahepatic 
RAAS plays important roles in both the pathophysiology 
of portal hypertension and liver fibrosis[18]. The use of 
ACE/AngⅡ/AT1R axis inhibitors associated with ACE2/
Ang (1-7)/Mas axis activation is a promising strategy-
serving regimen to prevent and treat chronic liver dis-
eases as well as acute liver injury[37]. Hepatic glucose 
metabolism can be modulated by NO directly inhibiting 
glycogen synthesis and gluconeogenesis, and indirectly 
inhibiting glycogen breakdown via the secretion of other 
intrahepatic mediators[38,39]. 
In the liver, both AngⅡ and Epi cause vasoconstriction 
and glucose release. Although the liver is not considered 
the target organ in hypertension pathophysiology, it 
is an important metabolic regulator organ. To study 
hepatic effects of AngⅡ and Epi, we used two different 
experimental models of hypertension: Pharmacological 
(systemic inhibition of NO synthase) and genetic (SHR). 
Chronic oral administration of L-NAME promotes a rapid 
deployment of hypertension in the first days of treatment 
that is largely mediated by the RAAS. The rats treated 
with ACE inhibitors, such as captopril and enalapril, or 
with AT1 receptor antagonists, such as losartan, restore 
blood pressure to near normal levels[40,41]. In our study, 
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Figure 2  Glucose release induced by angiotensin Ⅱ and epinephrine. Livers were perfused with Krebs-Henseleit-bicarbonate buffer and after stabilization 2 
nmol AngⅡ (A, B) or 40 nmol Epi (C, D) was injected in bolus into afferent cannula and this moment was considered as time 0 min. Glucose release was determined 
in perfusate aliquots collected during all experiments. Student’s t-test; aP < 0.05 and bP < 0.0001 compared with respective controls for each time point. WIS: Similar 
to normal rats; SHR: Spontaneously hypertensive rat; WKY: Wistar Kyoto; Ang: Angiotensin; Epi: Epinephrine.
Kimura DC et al . Hepatic effects of angiotensin Ⅱ and epinephrine
787 June 18, 2017|Volume 9|Issue 17|WJH|www.wjgnet.com
10 d of L-NAME treatment were sufficient to induce a 
high level systolic blood pressure. On the other hand, 
the SHR strain is the most widely used phenotypic ex-
perimental model in hypertension research with specific 
potential in the study of polygenic hypertension, being 
associated with cardiac hypertrophy, heart failure, and 
renal dysfunction. Hepatic functions are also altered at the 
molecular level in this model of primary hypertension[42].
Treatment with L-NAME did not affect fasting glucose 
levels but reduced significantly insulin levels in blood and 
increased insulin sensitivity of rats[43]. Gouveia et al[44] 
described increased glycemia and insulinemia values for 
fasted or fed SHRs. We observed normal glycemia and 
insulinemia in both hypertension models in fed state, 
which contrasts with the studies that show changes in 
these metabolic parameters. The discrepancy may be 
due to the metabolic states of the animals in the studies.
Tarsitano et al[43] described how prolonged treatment 
(2-8 wk) with NO synthase inhibitor enhanced hepatic 
glycogen levels. In our study, as the treatment with L-NAME 
was only for 10 d, the amount of liver glycogen was similar 
to the WIS group. This short period of treatment might 
not have been enough to observe possible changes in 
the glycogen content. Chronic or acute administration of 
an inhibitor of NO synthesis (L-NAME or L-NNMA) was 
shown to alter systemic RAAS, decreasing plasma level 
AngⅡ as well as renin activity[45]. Nevertheless, hepatic 
glucose release profile induced by AngⅡ in chronically 
treated L-NAME animals was similar to the control, which 
suggests that NO is not involved in the glucose release 
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Figure 3  Portal pressure induced by angiotensin Ⅱ or epinephrine. Livers were perfused with Krebs-Henseleit-bicarbonate buffer and after 20 min stabilization, 
2 nmol AngⅡ (A, B) or 40 nmol epinephrine (C, D) was injected in bolus into afferent cannula and this moment was considered as time 0 min. The portal pressure 
was continuously monitored by water manometer attached to the circuit before the cannula. Student’s t-test; bP < 0.0001 compared with respective controls for each 
time point. WIS: Similar to normal rats; SHR: Spontaneously hypertensive rat; WKY: Wistar Kyoto; Ang: Angiotensin; Epi: Epinephrine.
Glucose released µmol/min.g liver
Group Angiotensin Ⅱ n Epinephrine n
WIS 11.3 ± 0.9   7 7.5 ± 0.9 10
L-NAME 11.2 ± 1.5   7  4.2 ± 0.4d   8
WKY 16.4 ± 1.5   7 8.0 ± 0.9   8
SHR  5.42 ± 0.6b 10 5.9 ± 0.7   6
Table 2  Glucose release induced by angiotensinⅡ or epinephrine
The amount of glucose (area under the curve) was calculated from the 
curve glucose release increase vs time after agonist injection. Student’s t-test; 
bP < 0.0001 and dP = 0.002 compared with respective control (L-NAME vs 
WIS and SHR vs WKY). WIS: Similar to normal rats; SHR: Spontaneously 
hypertensive rat; WKY: Wistar Kyoto.
Portal hypertensive response cmH2O.min
Group Angiotensin Ⅱ n Epinephrine n
WIS 26.4 ± 3.2   7  8.2 ± 0.8 10
L-NAME 38.1 ± 4.8   7  18.5 ± 1.9b   8
WKY 29.0 ± 1.1   7 10.0 ± 1.1   8
SHR 25.9 ± 3.7 10 10.5 ± 1.1   6
Table 3  Portal hypertensive response to angiotensinⅡ or epinephrine
The portal hypertensive response (PHR; area under the curve) was 
calculated from portal pressure increase curve vs time after agonist injection 
and expressed as cmH2O.min. Student’s t-test; bP < 0.0001 compared with 
respective control (L-NAME vs WIS and SHR vs WKY). WIS: Similar to 
normal rats; SHR: Spontaneously hypertensive rat; WKY: Wistar Kyoto.
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after induction.
Interestingly, in the L-NAME group, the glucose 
release induced by Epi was lower than in the control 
group, suggesting that this effect may be related to the 
inhibition of NO synthesis. In cultured rat hepatocytes, 
Hodis et al[46] observed that glycogenolysis occurs via 
α-adrenergic stimulation and signaling cascade that 
involves the production of NO. Similarly, our results 
suggest that the chronic inhibition of NO synthase might 
inhibit hepatic glycogenolysis, which in turn decreases the 
release of glucose in the perfusate during the experiment. 
Therefore, the differences in glucose release following 
the L-NAME treatment evidenced that the increase in 
hepatic glycogenolysis was probably mediated by NO 
when activated by Epi but not by AngⅡ.
In the SHR group, it was described that muscle 
glycogen content was lower, but livers presented similar 
levels of glycogen in the fed and fasted states[44]. 
Likewise, we found similar amounts of liver glycogen in 
the SHR and WKY groups. Despite this similarity, after 
AngⅡ in bolus injection, glucose released was lower in 
the SHR group compared to the control group. This result 
suggests that glucose release is not necessarily related 
to glycogen content, but may be due to a possible 
difference in glycogen phosphorylase activation by 
increased [Ca2+]i induced by AngⅡ[47]. On the contrary, in 
this hypertension model, glucose release induced by Epi 
was similar when compared to the control.
Both AngⅡ and Epi are potent physiological vaso-
constrictors. We observed that although these agonists 
led to similar maximum increases of the portal pressure, 
AngⅡ promoted a higher PHR, even using doses 20-fold 
lower. These response differences may be related to 
the prolonged responses induced by AngⅡ in the liver 
or with the amount of AngⅡ receptor vs Epi receptor. 
An enhanced AngⅡ-mediated vasoconstriction was 
observed in healthy elderly individuals and this apparent 
increase is due, at least in part, to the potentiation of 
α-adrenergic vasoconstriction. These findings suggest 
that cross-talk between RAAS and adrenergic systems 
may be an important regulator of resting vascular 
tone and muscle blood flow with advancing age[48]. 
Cross-talk between the α1-adrenergic receptor (α1R) 
and AT1R potentially exists on two levels: Receptor 
heterodimerization between α1R and AT1R and second 
messenger level[49].
No difference in the PHR of AngⅡ in the pharma-
cologic hypertensive model was found, which suggests 
no changes in the expression of hepatic AT1 receptor. 
Our result contrasts with AT1R up-regulation described in 
the L-NAME model in other tissues such as the aorta[50], 
adrenals[51] and heart[52].
On the other hand, in L-NAME-treated animals, 
Epi induced increased PHR. It was shown that in rats, 
chronic inhibition of NO synthase produces endothelial 
dysfunction, increased vascular response to adrenergic 
stimulation, and perivascular inflammation[53]. NO is also 
involved in regulation of sympathetic nerve activity in 
human skin and muscle cells[54]. Therefore, this increased 
hypertensive effect in the liver of L-NAME-treated rats 
may be related to increased sympathetic vascular 
activity. The disparity between the effects of portal 
vasoconstriction (higher) and glucose released (lower) 
in the L-NAME group is a further indication that these 
effects might be dissociated in two components: One 
with direct action in the hepatocyte and the other as a 
presinusoidal response.
We also observed similar vasoconstrictor effect of 
AngⅡ in the SHR group. Although in this strain, higher 
levels of AT1R gene expression was described in brain 
regions involved in arterial blood pressure control[55]. 
Despite widely described sympathetic hyperactivity in 
this model[56-58], in this work, PHR to Epi on SHRs was 
similar to the control group.
In conclusion, AngⅡ and Epi responses are altered 
in different ways in these two models of hypertension. 
Our results suggest that inhibition of NO production 
seems to be involved in the hepatic hemodynamic and 
metabolic effects induced by Epi but not by AngⅡ. 
Furthermore, diminished glucose release induced by Ang
Ⅱ in SHR is not related to glycogen content, but to the 
glycogen phosphorylase activation by AngⅡ, that is under 
investigation.
COMMENTS
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In a normal liver, angiotensin (Ang)Ⅰ is rapidly converted in AngⅡ by hepatic 
angiotensin converting enzyme, and AngⅡ promotes hypertensive response 
mediated by the AT1 receptor. Besides this hemodynamic effect, AngⅡ induces 
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in the liver. The hepatic response to AngⅡ and Epinephrine in hypertension has 
not been studied yet. Therefore, the relevance of this study is to understand the 
hepatic effects of these hormones in two different hypertensive models. 
Research frontiers
The RAAS and the catecholaminergic system are present in the normal liver. 
The interaction of RAAS with the catecholaminergic sympathetic nervous 
system in the liver of hypertensive animals might bring to light relevant aspects 
of the relationship among metabolic disorders such as hypertension, type II 
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No descript of hemodynamic and metabolic effects of the two hormones AngⅡ
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metabolic effects of the two hormones AngⅡ and Epi. Inhibition of NO production 
in the L-NAME model increased hepatic hemodynamic and metabolic effects 
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induced by AngⅡ in SHRs is not related to glycogen content. Therefore, the 
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system are overexpressed, elucidating the hepatic role of these systems, which 
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The portal hypertensive response represents the area under the curve and was 
calculated from the graphic: Portal pressure increase (cmH2O) vs time after 
agonist injection (min) and expressed as cmH2O.min. It considers not only the 
perfusion pressure increase but the effect of the agonist over time.
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